Get the Stockscreener App
2.26
2.26%
0.05
Proqr Therapeutics N V stock is traded at $2.26, with a volume of 460.69K.
It is up +2.26% in the last 24 hours and down -0.88% over the past month.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
See More
Previous Close:
$2.21
Open:
$2.18
24h Volume:
460.69K
Relative Volume:
1.56
Market Cap:
$237.78M
Revenue:
$7.05M
Net Income/Loss:
$-30.43M
P/E Ratio:
-5.9662
EPS:
-0.3788
Net Cash Flow:
$21.84M
1W Performance:
+10.24%
1M Performance:
-0.88%
6M Performance:
-11.72%
1Y Performance:
+6.60%
1-Day Range:
$2.1601
$2.33
1-Week Range:
$1.98
$2.33
52-Week Range:
$1.07
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
2.26 | 223.33M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-10-25 | Upgrade | Citigroup | Neutral → Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-29-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-08-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-30-23 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Dec-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-14-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-11-22 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Feb-11-22 | Downgrade | Stifel | Buy → Hold |
| Feb-01-22 | Initiated | Raymond James | Strong Buy |
| May-03-21 | Initiated | Stifel | Buy |
| Mar-25-21 | Reiterated | Citigroup | Buy |
| Nov-03-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-12-19 | Reiterated | Chardan Capital Markets | Buy |
| Dec-19-18 | Initiated | RBC Capital Mkts | Outperform |
| Nov-15-18 | Initiated | Citigroup | Buy |
| Sep-19-18 | Initiated | Evercore ISI | Outperform |
| Sep-26-17 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-20-16 | Initiated | Chardan Capital Markets | Neutral |
| Oct-15-14 | Initiated | Deutsche Bank | Buy |
| Oct-13-14 | Initiated | H.C. Wainwright | Buy |
View All
Proqr Therapeutics N V Stock (PRQR) Latest News
Custom strategy builders for tracking ProQR Therapeutics N.V.July 2025 Retail & Free AI Powered Buy and Sell Recommendations - Newser
Pattern Scan Adds ProQR Therapeutics N.V. to Watchlist2025 Winners & Losers & Accurate Entry/Exit Alerts - beatles.ru
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Real time breakdown of ProQR Therapeutics N.V. stock performanceQuarterly Growth Report & Capital Efficient Trading Techniques - Newser
Is now a turning point for ProQR Therapeutics N.V.Weekly Trade Recap & Precise Buy Zone Identification - Newser
Will ProQR Therapeutics N.V. see short term momentumOil Prices & Daily Momentum Trading Reports - Newser
How to track smart money flows in ProQR Therapeutics N.V.Long Setup & Fast Gain Swing Trade Alerts - Newser
Can ProQR Therapeutics N.V. hit a new high this monthJuly 2025 Decliners & Long-Term Growth Plans - Newser
Is ProQR Therapeutics N.V. stock a growth or value playPortfolio Performance Summary & Step-by-Step Swing Trade Plans - Newser
What data driven models say about ProQR Therapeutics N.V.’s futureJuly 2025 Opening Moves & Reliable Trade Execution Plans - Newser
How to build a dashboard for ProQR Therapeutics N.V. stockJuly 2025 Closing Moves & Advanced Swing Trade Entry Alerts - Newser
How to recover losses in ProQR Therapeutics N.V. stockTrade Entry Report & Step-by-Step Swing Trade Plans - Newser
How high can ProQR Therapeutics N.V. stock goJuly 2025 Intraday Action & Daily Stock Trend Reports - Newser
Chart based analysis of ProQR Therapeutics N.V. trendsEarnings Risk Report & High Return Stock Watch Alerts - Newser
Volume spikes in ProQR Therapeutics N.V. stock – what they meanWeekly Trade Review & Daily Chart Pattern Signal Reports - Newser
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Candlestick Signal Suggests Reversal in ProQR Therapeutics N.V.July 2025 Drop Watch & Capital Efficiency Focused Strategies - sundaytimes.kr
Can ProQR Therapeutics N.V. recover in the next quarterWeekly Market Report & Weekly Top Gainers Alerts - Newser
Statistical indicators supporting ProQR Therapeutics N.V.’s strengthJuly 2025 Opening Moves & Risk Controlled Swing Trade Alerts - Newser
Buy Signal for ProQR Therapeutics N.V. Stock Key Technical Indicators to WatchQuarterly Investment Review & Low Drawdown Momentum Ideas - Newser
Is ProQR Therapeutics N.V. stock entering bullish territoryEarnings Risk Summary & Risk Controlled Swing Trade Alerts - Newser
Published on: 2025-08-17 09:13:48 - metal.it
What to do if you’re stuck in ProQR Therapeutics N.V.Quarterly Investment Review & Safe Entry Momentum Tips - Newser
Live market analysis of ProQR Therapeutics N.V.Portfolio Profit Report & Technical Entry and Exit Alerts - Newser
Candlestick signals on ProQR Therapeutics N.V. stock todayWeekly Stock Recap & Accurate Buy Signal Alerts - Newser
How institutional ownership impacts ProQR Therapeutics N.V. stock2025 Earnings Surprises & Proven Capital Preservation Methods - Newser
What is the earnings history of ProQR Therapeutics N.V.Weekly Profit Analysis & Weekly Sector Rotation Insights - newsyoung.net
ProQR Therapeutics N.V. stock outlook for YEARPortfolio Growth Summary & Long-Term Growth Stock Strategies - Newser
Published on: 2025-08-16 03:26:16 - Newser
Can ProQR Therapeutics N.V. rally from current levels2025 Winners & Losers & Fast Exit and Entry Strategy Plans - Newser
Using economic indicators to assess ProQR Therapeutics N.V. potentialPortfolio Performance Report & Safe Capital Growth Plans - Newser
Real time alert setup for ProQR Therapeutics N.V. performance2025 Price Momentum & Short-Term Trading Alerts - Newser
Will breakout in ProQR Therapeutics N.V. lead to full recoveryJuly 2025 Drop Watch & Expert Curated Trade Setup Alerts - Newser
ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles - Investing.com Nigeria
Proqr Therapeutics N V Stock (PRQR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):